文献速递心脑血管急症

瑞替普酶对比阿替普酶治疗急性缺血性卒中:Meta分析

Reteplase versus alteplase for acute ischemic stroke: Meta-analysis.
PubMed 文献 · Am J Emerg Med · 2025-04-12
一句话结论Meta分析显示,在4.5小时内急性缺血性卒中患者中,瑞替普酶18+18 mg方案较阿替普酶0.9 mg/kg提高90天优良功能结局,症状性颅内出血和死亡率无显著差异。

该Meta分析检索电子数据库,纳入2项高质量随机对照试验(共1588例患者),比较瑞替普酶与阿替普酶在4.5小时内急性缺血性卒中患者中的疗效与安全性。瑞替普酶组833例(60例接受12+12 mg,773例接受18+18 mg),阿替普酶组755例接受0.9 mg/kg。瑞替普酶与更高的90天优良功能结局(mRS 0-1;OR 1.55,95%CI 1.23-1.95)、良好功能结局(mRS 0-2;OR 1.36,95%CI 1.04-1.77)和早期神经功能改善(OR 1.42,95%CI 1.16-1.73)相关。症状性颅内出血(OR 1.25,95%CI 0.64-2.47)和死亡率(OR 1.18,95%CI 0.72-1.92)无显著差异。18+18 mg剂量报告最佳获益。作者认为瑞替普酶可能是阿替普酶的可行替代,但需多国试验验证结果的普适性。

要点

  • 在4.5小时内急性缺血性卒中患者中,瑞替普酶较阿替普酶提高90天优良功能结局(mRS 0-1;OR 1.55,95%CI 1.23-1.95)。
  • 瑞替普酶组90天良好功能结局(mRS 0-2;OR 1.36,95%CI 1.04-1.77)和早期神经功能改善(OR 1.42,95%CI 1.16-1.73)均优于阿替普酶。
  • 症状性颅内出血(OR 1.25,95%CI 0.64-2.47)和90天死亡率(OR 1.18,95%CI 0.72-1.92)在两组间无显著差异。
  • 瑞替普酶18+18 mg剂量报告最佳获益,12+12 mg仅60例。
  • 作者认为瑞替普酶可能是阿替普酶的可行替代,但需多国试验验证普适性。

适用人群与场景

  • 4.5小时内就诊的急性缺血性卒中患者(纳入2项RCT)

处置流程与药物剂量

  • 瑞替普酶给药方案包括12+12 mg(60例)和18+18 mg(773例),18+18 mg剂量报告最佳获益。
  • 阿替普酶给药方案为0.9 mg/kg(755例)。

研究设计与关键结果

  • Meta分析纳入2项高质量RCT,共1588例患者;瑞替普酶组833例(60例12+12 mg,773例18+18 mg),阿替普酶组755例接受0.9 mg/kg。
  • 主要终点:90天优良功能结局(mRS 0-1)瑞替普酶优于阿替普酶(OR 1.55,95%CI 1.23-1.95);症状性颅内出血两组无显著差异(OR 1.25,95%CI 0.64-2.47)。
  • 关键次要终点:90天良好功能结局(mRS 0-2)OR 1.36(95%CI 1.04-1.77);早期神经功能改善OR 1.42(95%CI 1.16-1.73);90天死亡率OR 1.18(95%CI 0.72-1.92),均无显著差异。
  • 18+18 mg瑞替普酶剂量报告最佳获益。

证据类型、等级与局限

  • 证据类型:系统评价/Meta分析,纳入2项高质量随机对照试验。
  • 局限:作者指出需多国试验验证结果对更广泛人群的普适性。

对床旁实践的改变

  • 作者认为瑞替普酶(尤其18+18 mg)可能是阿替普酶用于卒中溶栓的可行替代,但需多国试验验证普适性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: The demand for more effective and safer thrombolytic agents for acute ischemic stroke (AIS) has been increasingly recognized. Reteplase is a mutant form of alteplase with practical advantages. Nevertheless, the role of reteplase in patients with AIS is uncertain.

METHODS: We searched electronic databases to identify randomised clinical trials (RCTs) comparing reteplase to alteplase in AIS patients presenting within 4.5 h. The primary outcomes were the 90-day excellent functional outcome (modified Rankin scale [mRS] of 0-1) and symptomatic intracerebral hemorrhage (sICH). Secondary outcomes included 90-day good functional outcome (mRS 0-2), early neurological improvement (ENI), and 90-day mortality. Odds ratios (ORs) with 95 % confidence intervals (CIs) were pooled using the fixed-effects model.

RESULTS: Of the 544 identified records, we included two high-quality RCTs (1588 patients). A total of 833 patients received reteplase (60 with 12 + 12 mg and 773 with 18 + 18 mg), while 755 patients received alteplase 0.9 mg/kg. Reteplase was associated with higher rates of excellent functional outcomes (OR, 1.55 [95 % CI, 1.23-1.95]), good functional outcomes (OR, 1.36 [95 % CI, 1.04-1.77]), and ENI (OR, 1.42 [95 %CI, 1.16-1.73]) compared to alteplase. Similar rates of sICH (OR, 1.25 [95 %CI, 0.64-2.47]) and mortality (OR, 1.18 [95 %CI, 0.72-1.92]) were noted. Optimal benefits were reported in patients treated with 18 + 18 mg of reteplase.

CONCLUSIONS: In this meta-analysis, reteplase, particularly at the 18 + 18 mg dose, was more effective than alteplase with comparable safety profiles. These findings suggest that reteplase could be a viable alternative to alteplase for stroke thrombolysis. Multinational trials are needed to validate the generalizability of these results to a broader population.

来源:Am J Emerg Med,查看原文。版权归原作者所有。

参考来源

  1. Alkhiri A, Salamatullah HK, Alturki F, et al. Reteplase versus alteplase for acute ischemic stroke: Meta-analysis. Am J Emerg Med. 2025. PMID: 40517710. doi:10.1016/j.ajem.2025.04.024

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。